Sector
Healthcare & Life Sciences
1,107 announced healthcare & life sciences deals, most recent first, with the firms that advised on each.
Most recent
SEARCH ALL 1,107 Latham & Watkins Advises Pelthos Therapeutics in Combination With Castle Creek Biosciences 3 Nov 2026
Latham Advises on Aspen Neuroscience’s US$140.6 Million IPO 3 Nov 2026
Latham & Watkins Advises on Bambusa Therapeutics’ Upsized US$168.9 Million IPO 3 Nov 2026
DLA Piper advises Retension Pharmaceuticals on initial public offering 28 Oct 2026
Sidley Represents Bolt Biotherapeutics in the Acquisition of Prana Therapies and Concurrent US$120 Million Private Placement Financing 27 Oct 2026
Sidley Represents ZAP Surgical as It Secures US$36 Million in Financing 27 Oct 2026
DLA Piper advises Starpharma on majority ownership of Petalion Therapeutics 27 Oct 2026
Latham Advises on Corxel Pharmaceuticals and Amanat Acquisition Corp.’s Business Combination Agreement to Create a Publicly Listed Obesity-Focused Biopharmaceutical Company 27 Oct 2026
Latham & Watkins Advises Arcus Biosciences on US$250 Million Public Offering of Common Stock 27 Oct 2026
Linklaters advises QIAGEN on recommended voluntary all-cash public takeover offer by EQT 27 Oct 2026
Clifford Chance advises Luxinva on the voluntary public takeover offer of QIAGEN NV 22 Oct 2026
Latham & Watkins Advises Cheplapharm on Private Placement 22 Oct 2026
Herbert Smith Freehills Kramer advises DKSH on its acquisition of NewBridge Pharmaceuticals 21 Oct 2026
Sidley Represents Savillex in Its Acquisition of Entegris’ Life Sciences Fluid Management Business 21 Oct 2026
Baker McKenzie Advises Lenders on USD 800 Million Bridge Financing for Galderma’s Acquisition of ZO Skin Health 21 Oct 2026
DLA Piper advises Arlington Capital Partners and Everest Clinical Research on acquisition of Firma Clinical Research unit 21 Oct 2026
TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX), a special purpose acquisition company (SPAC) sponsored by TCGX, have announced the execution of a definitive business combination agreement that will result in TriGemX Bio becoming a publicly traded company. The combined company will be named TriGemX Bio, Inc. and is expected to trade on Nasdaq under the new ticker symbol TGEM. Latham & Watkins LLP represents TCGX in the transaction with a corporate team led by Houston partners Ryan Maierson and Ryan Lynch, with associates Taylor Allison, Cooper Shear, and Luisa Gomez Yokubaitis, with assistance from Zachary Mouton. Advice was also provided on tax matters by Houston partner Jared Grimley, with associates Dominick Constantino and Graham Core; on benefits matters by Los Angeles partner Michelle Carpenter, with associate Jordan Barnes; on healthcare regulatory matters by Washington, D.C. partner Nathan Beaton and counsel Nicole Liffrig Molife and Chad Jennings, with associate Margaret Rote; on funds matters by Chicago partner David Moore and New York partner Jennifer Tian;* on data cybersecurity matters by New York partner Jessica Cohen, with associates Laura Geraci and Nat Lewis; on data privacy and cybersecurity matters by Bay Area partner Heather Deixler, with associate Ryleigh Chen; on environmental matters by Los Angeles/Houston partner Joshua Marnitz, with associate Brandon Kerns; on anti-bribery and anti-money laundering matters by Washington, D.C. partner Daniel Dominguez, with associates Patricia Amselem Bensadon and Ai Ni Lim; on antitrust matters by Washington, D.C. partner Jason Cruise and Washington, D.C. counsel Ngoc Hulbig; and on economic sanctions and export controls matters by Washington, D.C. partner Eric Volkman, with associate Amulya Vadapalli. *Admitted to practice in Illinois only. 21 Oct 2026
Sidley Represents Aquestive Therapeutics in Exclusive U.S. Licensing Agreement With Eton Pharmaceuticals 19 Oct 2026
DLA Piper advises Lanas on acquisition of New Zealand healthtech provider indici 19 Oct 2026
Latham & Watkins Advises Zocdoc on Acquisition of Sohar Health 19 Oct 2026
Latham & Watkins Advises RxSight on Collaboration With Alcon to Develop Adjustable PCIOLsLatham & Watkins Advises RxSight on Collaboration With Alcon to Develop Adjustable PCIOLs 19 Oct 2026
Latham Represents BlackRock and HPS Investment Partners in New Strategic Joint Venture With Humana to Manage CenterWell Senior Primary Care Clinics 14 Oct 2026
Latham Advises on Financing for Altaris’ Completed Acquisition of Clarivate’s Life Sciences & Healthcare Business 13 Oct 2026
Latham & Watkins Advises Partners Group on Refinancing of DELABO.group 13 Oct 2026
Latham & Watkins Advises Cheplapharm on €1.2 Billion Term Loan B 13 Oct 2026
Latham Advises on TRexBio’s US$116.7 Million Initial Public Offering 12 Oct 2026
Latham Advises H.I.G. Capital and Medisolve on Refinancing and Growth Financing 9 Oct 2026
Sidley Represents GE HealthCare in Its US$945 Million Acquisition of SOFIE Biosciences 8 Oct 2026
Latham & Watkins Advises on Rocket Pharmaceuticals’ Growth Facility 8 Oct 2026
Latham Advises on Vaxcyte’s Concurrent Public Offerings of Common Stock, Pre-Funded Warrants, and Convertible Senior Notes 8 Oct 2026
Latham & Watkins Advises Spectrum Equity on Growth Investment in Symmetric Health Solutions 7 Oct 2026
Sidley Represents Telix Pharmaceuticals in Its US$1.65 Billion Merger With ITM 7 Oct 2026
DLA Piper advises IntraBio on US$2.0 billion acquisition by Shionogi 7 Oct 2026
Latham Advises Arsenal Medical in Acquisition by Terumo Neuro 6 Oct 2026
Sidley Represents Jiangsu Hengrui in Connection With US$2.6 Billion Licensing Agreement With Novo Nordisk 2 Oct 2026
Sidley Represents Pyxis Oncology in an up to US$282.6 Million Public Offering 2 Oct 2026
Latham & Watkins Advises Shareholders on Sale of SK Pharma to Arcus Infrastructure Partners 2 Oct 2026
Linklaters advises Fresenius on the full acquisition of the biopharmaceutical company mAbxience 2 Oct 2026
Sidley Represents Jiangsu Nhwa Pharmaceutical in Its US$517.5 Million Licensing Transaction With Somnivera 1 Oct 2026
Latham Advises on Pyxis Oncology’s Up to US$282.6 Million Public Offering 1 Oct 2026
Hogan Lovells Cadwalader advises Ligand on financing agreement with AvenCell Therapeutics 30 Sept 2026
Latham & Watkins Advises Grünenthal on Issuance of €850 Million High-Yield Bond 30 Sept 2026
Sidley Represents Star51 Capital in Its Investment in UltraSight’s US$24 Million Financing 28 Sept 2026
Latham & Watkins Advises on ADARx Pharmaceuticals’ Upsized US$446.3 Million Initial Public Offering 28 Sept 2026
Dentons advises R1 on acquisition of Humata Health 25 Sept 2026
Latham & Watkins Advises Life Science Intelligence on Strategic Partnership With Opus Origin 25 Sept 2026
Latham Advises on Viking Therapeutics’ Upsized US$500 Million Offering of Common Stock and Convertible Senior Notes 25 Sept 2026
Baker McKenzie Advises Bayer on the Sale of Cancer Treatment Stivarga® to Grünenthal 24 Sept 2026
Latham & Watkins Advises on Vaderis Therapeutics’ US$152 Million Series B Financing 24 Sept 2026
Sidley Represents Sheridan Capital Partners in Its Investment in PtEverywhere 23 Sept 2026
Herbert Smith Freehills Kramer advises Telix Pharmaceuticals Limited on its transformational merger with ITM Isotope Technologies Munich SE 22 Sept 2026
Hogan Lovells Cadwalader advises Barings, Bridgepoint and Pemberton on the financing of Inflexion’s acquisition of Primed Group 21 Sept 2026
Latham & Watkins Advises on Electra Therapeutics’ Upsized US$350 Million Initial Public Offering 21 Sept 2026
Latham & Watkins Advises Novo Nordisk in Multi-Target Drug Discovery Partnership With Orbis Medicines Worth Up to US$1.4 Billion 21 Sept 2026
Sidley Represents Verily Health in Investment from NVIDIA 17 Sept 2026
Hogan Lovells Cadwalader advises on US$209 million Symbiotec Pharmalab IPO 17 Sept 2026
Latham Advises on Beta Bionics’ US$150 Million Public Offering of Common Stock and Pre-Funded Warrants 17 Sept 2026
Latham & Watkins Advises Thatch on US$108 Million Series C 17 Sept 2026
Latham Represents Neuberger and KKR in Investment in Datavant Alongside New Mountain Capital 17 Sept 2026
Latham & Watkins Advises Cheplapharm on Strategic Partnership With Sanofi 17 Sept 2026